In conclusion, we have identified a range of assays and biomarkers of COVID-19 immunity that will be used to define CoP in future studies using serum and plasma samples sequentially collected from these or similar cohorts, or notably, from vaccination breakthrough or re-infection cases. This evidence concerns the gene CARD16 and COVID-19.